CervoMed reports Q3 2026 results, says cash insufficient to fund operations for 12 months

CervoMed Inc. reported its Q3 2026 financial results, saying grant revenue has concluded and current cash resources are insufficient to sustain operations for the next 12 months. It said initiation of a Phase 3 trial for its dementia with Lewy bodies program depends on securing additional funding or a strategic partnership.

Detected & updated continuously · Source: Nebula